Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM

NCT03948035 is registered in ClinicalTrials.gov with Wuerzburg University Hospital as lead sponsor.

NCT NCT03948035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03948035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM
Lead sponsor
Wuerzburg University Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 28, 2018
Completion date
August 31, 2029
Enrollment
576 (estimated)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed multiple myeloma